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Antiviral Activity of Synthetic Aminopyrrolic 
Carbohydrate Binding Agents. Targeting the 
Glycans of Viral gp120 to Inhibit HIV Entry. 
Oscar Francesconi,*[a] Cristina Nativi,[a] Gabriele Gabrielli,[a] Irene De Simone,[a] Sam Noppen,[b] Jan 
Balzarini,[b] Sandra Liekens[b] and Stefano Roelens[c] 
 
Abstract:. The binding abilities of a set of structurally related 
aminopyrrolic synthetic receptors for mannosides, endowed with 
antimycotic activity against yeast and yeast-like pathogens bearing 
mannoproteins on their cell surface, have been investigated towards 
the highly mannosylated gp120 and gp41 glycoproteins of the HIV 
envelope. A pronounced binding interaction with both glycoproteins 
was observed by SPR for most of the investigated compounds. 
Comparison of their binding properties towards the glycoproteins 
with their binding affinities toward mannosides revealed a direct 
correlation, supporting their role as carbohydrate binding agents 
(CBAs). Cytostatic activity studies revealed antiproliferative activity 
dependent on the nature and the structure of compounds. Antiviral 
activity studies against a broad panel of DNA and RNA viruses, 
showed an inhibitory effect against HIV infection of T-lymphocyte 
CEM cells for two compounds, suggesting antiviral activity similar to 
other CBAs, such as the non-peptidic pradimicin antibiotics. 
Introduction 
The carbohydrates of the glycocalyx, exposed on the surface of 
eukaryotic cells, are critically involved in the modulation of the 
immune system and in cell adhesion processes.[1] Many 
pathogenic microorganisms, including several viruses, are also 
covered by a glycoconjugate coating, which is used to promote 
adhesion to and infection of the host cells through carbohydrate 
recognition processes.[2] The densely mannosylated N-glycans 
of the viral envelope of the human immunodeficiency virus (HIV) 
play a crucial role in viral transmission. The glycan coating also 
acts as a shield for the virus, hiding the underlying immunogenic 
epitopes in order to escape from the immune system of the 
host.[3,4] 
Recently, the highly mannosylated glycoprotein gp120 of 
the HIV envelope has been proposed as a target for new 
therapeutic strategies.[4a,b] Lectins of various origins, capable of 
interacting with gp120, turned out to effectively inhibit infection 
and transmission of HIV by blocking the virus entry process to 
the host cell.[4c,d] For example, microvirin exerts a potent 
inhibitory activity toward HIV-1 infection (IC50 = 2-12 nM) by 
selectively recognizing the Manα(1-2)Man motif of the gp120 
viral protein.[5a,b] Moreover, long-term exposure to dose-
escalating concentrations of lectins causes several mutations in 
the viral gp120, predominantly affecting the N-glycosylation sites. 
As a result, the partially deficient glycosylated envelope 
uncovers immunogenic epitopes, which are thus exposed to the 
immune system and may trigger a humoral response.[6a] Hu et al. 
have indeed demonstrated that cyanovirin-exposed HIV-1 
strains that had a few deleted N-glycosylation motifs in gp120, 
were more susceptible to the inhibitory activity of several gp120-
targeting monoclonal antibodies.[6b] This dual activity mechanism 
makes the use of carbohydrate binding agents (CBAs) very 
attractive. 
Unfortunately, lectins present many drawbacks which 
prevent their development as therapeutic agents, mainly due to 
their high molecular weight and their peptidic nature.[4c,d] 
Therefore the development of small-size nonpeptidic molecules 
as CBAs is recently emerging as a promising strategy for 
antiviral therapies and vaccines. For example, the nonpeptidic 
antibiotic Pradimicin A (PRM-A) and its more soluble analogue 
Pradimicin S (PRM-S), which have been found to bind to the 
terminal mannosides exposed on fungal membranes,[7,8] showed 
antiviral activity against HIV-1, with 50% effective concentrations 
(EC50’s) in the low micromolar range.[9a-c] Non-peptidic 1,3,5-
triazines, shown to bind to gp120 and to inhibit HIV-1 in cell 
culture, have also been reported,[9d] as well as glycan-binding 
benzoboroxole-functionalized polymers.[9e,f] Thus, the search for 
new (preferably non-peptidic) CBAs is a topic of growing interest 
in the current literature. 
In the last few years we have developed a family of 
structurally-related synthetic aminopyrrolic receptors for 
biomimetic recognition of mono- and disaccharides of biological 
interest.[10] They were found to bind to mono- and dimannosides 
in competitive organic solvents with affinities in the low 
micromolar range by exploiting a combination of hydrogen 
bonding and van der Waals/CH-π interactions.[11] The progenitor 
of this family is the tripodal aminopyrrolic receptor 1 whose 
structure interestingly presents close similarities with the 
architecture of the primary mannose binding site of PRM-A, as 
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Chart 1. Set of the aminopyrrolic compounds investigated in this study. 
Table 1. Binding affinities (BC500, mM) of compounds 1 to 10 for octyl mannosides in CD3CN. [a] 
 1 2 3 4 5 6 7 (S)-8 (R)-8 (S)-9 (R)-9 10 
OctαMan 15.6 n.d. 22.0 n.d. 98.0 12.0 8.20 0.65 1.16 0.44 0.13 4.00 
OctβMan 7.40 n.d. 20.6 n.d. 44.5 5.90 8.00 0.42 1.34 0.57 0.87 0.65 
[a] Formation constants (log β) were measured by 1H NMR (400 MHz) from titration experiments at T = 298 K. Data from previous works (see ref 11b and 13). 
Intrinsic Median Binding Concentration (BC500) values were calculated from the (log β ) values using the “BC50 Calculator” Program (see ref. 15). 
suggested by Ito and Nakagawa.[12a,b] In order to evaluate the 
efficacy of these receptors as CBAs, we have recently tested 
their biological activity toward several strains of yeast and yeast-
like microorganisms, which present a close carbohydrate 
similarity between the mannan portion exposed on their cell 
surface and the oligomannose glycans of the gp120 glycoprotein 
of the viral envelope of HIV.[13] The results obtained against 
different pathogenic microorganisms, like Pichia norvegensis 
and Prototheca wickeramii, demonstrated antifungal activity and 
cytotoxicity comparable to commercial antifungal drugs like 
Amphotericin B and Ketoconazole. Moreover, localization 
studies on treated cells suggested that the interaction of these 
compounds with the surface glycans represents a key step in 
the internalization into the cell, where they exert their antibiotic 
activity. 
Because of the close similarity of the mannan portion of 
yeast cell wall with the HIV gp120 glycans,[14] we carried out an 
investigation on the antiviral activity of this family of synthetic 
receptors. We report in the present paper the results of such a 
study on the inhibitory activity of a set of synthetic aminopyrrolic 
receptors against viruses of high health concern, such as HIV. 
The cytostatic activities of the investigated compounds were 
also examined, to be compared to their antiviral activities. 
Results and Discussion 
Chemistry. The set of investigated molecules (Chart 1) was 
obtained from structural modifications of the parent tripodal 
aminopyrrolic receptor 1, which exhibited the most interesting 
biological activities towards yeasts. The modifications carried out 
concerned: i) dissection of the architecture into the constituting 
structural elements (2 and 3); ii) variation of the number of 
aminopyrrolic binding arms on the benzene platform (4, 5, 6 and 
7); iii) introduction of additional aminic binding groups inserted 
between the pyrrolic and the benzenic ring ((S)-8, (R)-8, (S)-9 
and (R)-9) or on position 5 of the pyrrole ring (10). All molecules 
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Figure 1. SPR analysis of the binding of compounds 1-10 to gp120 (a, b and c, chip density 3256 RU) and to gp41 (d, e and f, chip density 3703 RU) injected as 
a 5% DMSO solution over the surface at a fixed concentration of 50 μM. Running buffer was HBS-P at pH 7.4 containing 10mM of Ca2+. 
Molecular Recognition Studies. The set of aminopyrrolic 
compounds was subjected to Surface Plasmon Resonance 
(SPR) analysis to determine their ability to interact with the 
highly mannosylated N-glycans of the HIV viral envelope 
glycoproteins gp120 and gp41. From previous observations in 
highly competitive organic media (acetonitrile), the investigated 
molecules showed interesting binding affinities towards 
mannose glycosides (Table 1). While molecules 2 and 4 showed 
a negligible binding ability, the remaining receptors showed 
affinities ranging from high-millimolar (98.0 - 44.5 mM) for 5 to 
low-millimolar (22 - 5.90 mM) for 1, 3, 6 and 7 to submillimolar (4 
- 0.13 mM) for (S)-8, (R)-8, (S)-9, (R)-9 and 10.[11b, 13] The glycan 
recognition properties were thus investigated towards the 
glycoproteins gp120 and gp41 of the HIV envelope, covalently 
immobilized on a SPR sensor chip. Since recognition of these 
glycans by several CBAs of both peptidic and non-peptidic origin, 
such as C-type lectins (e.g. MBL, DC-SIGN) and the non-
peptidic pradimicin antibiotics, is driven by a Ca2+-dependent 
carbohydrate binding,[9,14] a 10 mM concentration of calcium was 
used in the experimental set-up. To help the dissolution of the 
investigated molecules, 5% v/v DMSO was added to the HBS-P 
buffer solution at pH 7.4. 
 In a first series of experiments (Figure 1), binding of the 
compounds to gp120 and gp41 was investigated, using high 
density gp120 (3,256 RU) and gp41 (3,703 RU) sensor chips. 
The compounds were injected at a relatively high concentration 
(50 μM) to the HD chips to enable detection of potentially low 
binding affinities for the compounds. Interestingly, most of the 
investigated compounds showed a pronounced interaction with 
gp120 and gp41 (Figure 1). However, striking differences in 
terms of binding amplitude were observed among the set of 
compounds. Molecules 7 and 10 showed the strongest binding 
of the series for both glycoproteins (RU ~ 75), followed by (S)-8, 
(R)-8 (RU between 50 and 75); an intermediate binding 
amplitude was observed for compounds 1, 3, 6, (S)-9 and (R)-9 
(RU between 20 and 45). Finally, compounds 2, 4 and 5 showed 
the poorest (RU << 20) interaction with both viral glycoproteins 
(RU < 20). Aspecific interactions were separately tested in a 
second set of experiments (Figure S1), in parallel with the 
gp120/gp41 interaction experiments, by examining the binding 
amplitude generated by the investigated compounds when 
exposed to a HSA (non-glycosylated human serum albumin) 
(5,520 RU) sensorchip. In general, the order of binding 
magnitude of the compounds to gp120 and gp41 in this 
experiment was virtually identical to that of the previous 
experiment reported in Figure 1. Interestingly, all compounds 
presented a rather weak interaction with human serum albumin, 
with the exception of compound 10, which showed a 
pronounced binding amplitude (~ 65 RU). Probably, the 
propensity to establish aspecific interactions with non-
glycosylated proteins provides an additional (but not 
predominant) contribution to the binding abilities observed 
toward gp120 and gp41. 
 From the comparison of binding abilities observed via SPR 
through immobilized gp120 and gp41 with the data previously 
obtained in acetonitrile for mannoside interaction, a direct 
correlation became apparent. In particular, while the 
submillimolar affinities for mannosides measured for compounds 
(S)-8, (R)-8, (S)-9, (R)-9 and 10 are reflected by a high 
interaction observed with gp120 and gp41, poor or negligible 
affinities of compounds 2, 4 and 5 are reflected by the absence 
of significant interactions with the glycoproteins. This evidence 
suggests that the interaction between the investigated 
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the molecular recognition of the high-mannose type glycans. In 
analogy to other non-peptidic CBAs, such as PRM-A and PRM-
S, these compounds may recognize the mannose residues, 
promoting their adhesion to the immobilized gp120 and gp41. 
 
Cytostatic activity. The binding interaction observed via SPR 
suggested a potential role of the investigated molecules as 
CBAs and encouraged further investigation of their biological 
properties. The in vitro toxicity against HuH-7 (Human 
Hepatoma) cells of compound 1 was reported in a previous 
paper. Thus, cytostatic activity of the whole set of molecules was 
investigated against human CD4+ T-lymphocyte CEM, murine 
leukemia L1210, and human cervix carcinoma HeLa cell lines 
(Table 2). The inhibitory effect  
Table 2. Inhibitory effects of the compounds on the proliferation of murine 
leukemia (L1210) and human T-lymphocyte (CEM) and human cervix 
carcinoma (HeLa) cells.) 
Compound 
IC50a (µM) 
L1210 CEM HeLa 
1 0.91 ± 0.17 0.88 ± 0.09 0.94 ± 0.21 
2 > 250 > 250 > 250 
3 22 ± 3 19 ± 3 19 ± 3 
4 17 ± 3 18 ± 0 21 ± 3 
5 0.83 ± 0.17 1.2 ± 0.3 3.1 ± 1.9 
6 88 ± 38 92 ± 22 138 ± 60 
7 58 ± 30 90 ± 16 123 ± 60 
(S)-8 9.6 ± 6.3 7.5 ± 3.6 9.4 ± 1.7 
(R)-8 8.6 ± 5.4 4.1 ± 0.8 4.6 ± 1.3 
(S)-9 0.70 ± 0.18 0.85 ± 0.07 0.77 ± 0.05 
(R)-9 0.67 ± 0.07 0.82 ± 0.02 0.89 ± 0.09 
10 89 ± 18 74 ± 5 24 ± 4 
[a] a50% inhibitory concentration or compound concentration required to 
inhibit cell proliferation by 50%. 
measured showed a similar trend on the three different cell lines, 
whereas the antiproliferative activity markedly varied depending 
the nature and structure of compounds. Compounds containing 
the 1,3,5-triethylbenzene scaffold and featuring two or three 
aminopyrrolic binding arms (1, 5) were markedly cytostatic. 
When the ethyl groups were removed from the scaffold of the 
parent molecule 1, the resulting compound 3 exhibited a more 
than 20-fold decrease in cytostaticity. The tetra- and hexa-
aminopyrrolic compounds lacking ethyl groups were poorly 
cytostatic (i.e., IC50 for compounds 6 and 7: ∼ 100-fold higher 
than the IC50 of compound 1). Thus, the specific 
substitution/conformation of the scaffold apparently plays a role 
in the cytostatic activity of these compounds. The presence of 
ethyl groups on the phenyl core, in addition to at least 2 or 3 
aminopyrrolic arms, appears to be responsible for the 
appearance of cytostatic activity. However, it is noteworthy that 
compound 10, possessing an amino group in position 5 of 
pyrroles, unexpectedly lost its cytostatic activity compared to 
compound 1. 
 Compounds (S)-8, (R)-8, (S)-9 and (R)-9 represent further 
examples that show that the ethyl groups on the phenyl core are 
relevant for cytostatic activity. Moreover, compounds (S)-9 and 
(R)-9 (containing three pyrrolic side-arms) were more cytostatic 
than compounds (S)-8 and (R)-8 that contain only one pyrrole 
within the macrocyclic architecture. It was also interesting to 
note that the different (S and R) stereochemistry of the 8 and 9 
compounds did not affect their cytostatic activities. 
 
Antiviral Activity. The ability of the investigated compounds to 
protect CEM cells against the cytopathogenicity of HIV-1 and 
HIV-2 was evaluated to examine their antiviral activity (Table 3). 




1 >0.4 >0.4 
2 > 250 > 250 
3 >10 >10 
4 >10 >10 
5 >2 >2 
6 >50 >50 
7 16 ± 0.0 24 ± 2.1 
(S)-8 >2 >2 
(R)-8 >2 >2 
(S)-9 >0.4 >0.4 
(R)-9 >0.4 >0.4 
10 1.7 ± 1.5 50 ± 0.0 
[a] a50% inhibitory concentration or compound concentration required to 
inhibit cell proliferation by 50%. 
Among the tested compounds 7 and 10 that showed the highest 
binding efficiency to gp120/gp41 exerted pronounced inhibitory 
effects against HIV infection. In particular, compound 10 showed 
the highest inhibitory activity against the HIV-1 infection (EC50 
HIV-1: 1.7 µM), although it was markedly less active against 
HIV-2 (EC50: 50 µM). Interestingly, compound 10 was poorly 
cytostatic. Apparently, there does not seem to exist an obvious 
correlation between gp120/gp41 binding and anti-HIV-1 activity 
in cell culture. This can be explained by considering that a 
number of compounds may bind to non-neutralizing parts of the 
gp120 glycoprotein, which do not affect the gp120/gp41-driven 
viral entry into the target cells. It should, however, also be noted 
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9 were fairly toxic to the cell cultures, thereby masking a 
potential antiviral activity. None of the compounds showed 
inhibitory activity against a broad panel of DNA and RNA viruses 
(Tables in Supporting Information), except for compound 7 that 
was found to be active against respiratory syncytial virus (RSV), 
showing an EC50 of 4 µM. 
Conclusions 
In the present work a set of structurally related synthetic 
aminopyrrolic receptors for mannosides, endowed with 
antimycotic activities against yeast and yeast-like pathogens 
presenting on their cell wall high-mannose-type glycans, has 
been investigated to ascertain the ability to target the HIV high-
mannose-type glycans of the gp120 glycoprotein and to exert 
antiviral activity. Binding measurements towards gp120 and 
gp41, obtained by SPR, demonstrated a good correlation 
between mannose recognition and interaction with the 
glycoprotein. Moreover, compounds 7 and 10, which are the 
least cytostatic compounds of the set, demonstrated a significant 
inhibitory effect against HIV infection of T-lymphocyte CEM cells, 
suggesting that they possess antiviral activity like other CBAs, 
such as PRM-A and PRM-S. Thus, this new family of CBAs 
targeting gp120 and gp41, and showing anti-HIV activity, may be 
considered as potential novel anti-HIV lead candidates to be 
further developed. 
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Aminopyrrolic synthetic receptors for mannosides, capable of interacting with the 
gp120 and gp41 glycoproteins of the HIV viral envelope, have demonstrated 
significant inhibitory activity against HIV infection of T-lymphocyte CEM cells, 
together with a poor cytostatic activity. 
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